LRI Investments LLC Makes New Investment in Kenvue Inc. (NYSE:KVUE)

LRI Investments LLC bought a new position in Kenvue Inc. (NYSE:KVUE) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 4,953 shares of the company’s stock, valued at approximately $106,000.

Other large investors have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC increased its holdings in shares of Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the period. Pacific Capital Wealth Advisors Inc. bought a new position in Kenvue during the fourth quarter valued at about $28,000. Mather Group LLC. bought a new position in Kenvue during the first quarter valued at about $28,000. Oakworth Capital Inc. bought a new position in Kenvue during the first quarter valued at about $31,000. Finally, Pinnacle Bancorp Inc. boosted its stake in Kenvue by 51.3% during the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after buying an additional 526 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Up 1.0 %

Shares of NYSE KVUE opened at $18.82 on Friday. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.43. The firm has a market capitalization of $36.04 billion, a PE ratio of 24.13, a PEG ratio of 2.07 and a beta of 1.38. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $18.49 and a two-hundred day moving average price of $19.45.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $3.79 billion. The firm’s revenue was down 24.9% compared to the same quarter last year. As a group, analysts predict that Kenvue Inc. will post 1.13 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.36%. Kenvue’s dividend payout ratio (DPR) is 102.56%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Sanford C. Bernstein assumed coverage on Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. HSBC raised their target price on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. Citigroup decreased their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft decreased their price target on Kenvue from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Finally, JPMorgan Chase & Co. decreased their price target on Kenvue from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Monday, July 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $22.45.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.